Evommune, Inc. (EVMN) Cash Flow Statement
Evommune, Inc. (EVMN) generated -$74.2M of operating cash flow over the twelve months to 2026-06-30, spent $501000 on capital expenditure and had free cash flow of -$74.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EVMNEvommune, Inc.Follow EVMN — free
—
Price chart with a free account
- Market cap
- 185.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Dec, in 46 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -58.2 | -76.4 | -74.2 | |
| Capital expenditure | 0.1 | 0.2 | -0.5 | |
| Free cash flow | -58.3 | -76.7 | -74.7 | |
| Dividends paid | 1.5 | — | — | |
| Stock-based compensation | 1.7 | 5.9 | — |
USD millions · SEC XBRL
Evommune, Inc. — questions
- What is Evommune, Inc.'s operating cash flow?
- -$74.2M over the twelve months to 2026-06-30.
- How much does Evommune, Inc. spend on capital expenditure?
- $501000 over the twelve months to 2026-06-30.
- What is Evommune, Inc.'s free cash flow?
- -$74.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Evommune, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.